Sagimet Biosciences (SGMT) Net Income towards Common Stockholders (2022 - 2026)

Sagimet Biosciences' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 30.91% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$69.9 million (up 46.13% YoY), while the FY2025 annual figure was -$54.8 million, up 51.02% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$13.8 million, down from -$13.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$6.7 million in Q1 2023, with the low at -$82.6 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$15.1 million (2024), against an average of -$21.8 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders tumbled 657.31% in 2024, then surged 83.82% in 2025.
• Sagimet Biosciences' Net Income towards Common Stockholders stood at -$55.0 million in 2022, then soared by 80.18% to -$10.9 million in 2023, then sank by 657.31% to -$82.6 million in 2024, then soared by 83.82% to -$13.4 million in 2025, then declined by 3.37% to -$13.8 million in 2026.
• Business Quant data shows SGMT's Net Income towards Common Stockholders at -$13.8 million in Q1 2026, -$13.4 million in Q4 2025, and -$20.0 million in Q3 2025.